Bride's new toilet points to social revolution

July 4, 2012

Bride_new

Vishnupur Khurd (Uttar Pradesh), July 4: Spotlessly clean and decorated with plastic flowers and balloons for its opening ceremony, Priyanka Bharti’s toilet is seen as a gleaming symbol of the empowerment of Indian women.

It has been built in the village of Vishnupur Khurd in Uttar Pradesh state due to the determination of Priyanka, a young bride who walked out of her new marital home when she was appalled to find she had to defecate in the open.

The ensuing drama soon became well-known in the area as the newlyweds’ scandalised families both tried to persuade her to return to her husband but she refused, saying the shame of squatting in the fields was too much to bear.

“I was adamant that I could not stay in a home where people might see me go to the toilet outside in an unhygienic way,” Priyanka said after the lavatory, constructed by sanitation charity Sulabh, was ceremonially unveiled last week.

“I don't know where I got the strength,” she said. “But I come from a family with many strong women and when I moved to my husband’s house I was without my relatives and friends and I was having to adjust to a new life.”

Her firm stance paid unexpected dividends after Sulabh, one of India’s largest social organisations, heard about her protest and adopted her cause as a way to promote better public health through proper toilet facilities.

It even awarded Priyanka a Rs200,000(Dh13,205) prize that was presented at the official opening of the small toilet building, with the bride agreeing to move back in with her husband.

“We did not really believe the money was a true story, so we are shocked,” said Priyanka, whose marriage was arranged when she was aged just 14, although she was not taken to her husband until April when she turned 19.

She stayed at her new home for just four days before fleeing when her family came to visit from their village 20 kilometres (12 miles) away. She refused to return to the marital home until the toilet was ready to use.

“My parents were apprehensive and angry but I convinced them it was what I had to do. They had a basic indoor toilet, so for me to start going outside was too difficult,” she said.

Defecating in the open is a major social issue in India, touching on topics including women’s rights, health and hygiene, and the clash between traditional and modern lifestyles.

“Women will not go in the open during the day so they must visit the fields before dawn and then wait many hours again until after dusk,” Bindeshwar Pathak, who founded Sulabh in 1973, said.

“Walking barefoot in these areas is bad for catching tapeworm, bacteria and many other diseases, and is unhealthy for children who play. People used to not talk about this issue but now it is a public debate.”

Pathak, one of India’s most notable activists, has for decades campaigned for the use of simple indoor toilets and has also fought for low-caste Dalits (formerly “untouchables”) who often clean out other people’s bucket toilets.

“We gave awards to Priyanka and two other brides who refused to live with their new families due to lack of toilets,” he said. “We want them to be torchbearers whose example encourages better sanitation.”

India’s Rural Development Minister Jairam Ramesh said recently that India “should be ashamed” that 60 to 70 per cent of women are forced to defecate in the open and he vowed further funding to tackle the problem.

However, government schemes to build new facilities are often undermined by corruption, with recent allegations that in Uttar Pradesh alone, millions of toilets meant to have been built by state authorities were never constructed.

According to the 2011 census, about 131 million households in India have no latrine in their premises, with eight million using public facilities and 123 million defecating in the open.

Among those with an indoor toilet, 800,000 households use a bucket device cleaned by humans and 500,000 use containers left out for animals to eat from.

In Vishnupur Khurd, the new toilet block, with its freshly-painted yellow walls, stands out among the jumble of huts and houses made of rough bricks.


Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 30,2020

Hyderabad, Jun 30: Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company's Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.

Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: "We are proud to announce COVAXIN, India's first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine."

Dr Ella added, "The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform."
Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech's prowess, Suchitra Ella, Joint Managing Director said, "Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic."
"Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India's strength in handling future pandemics," she added.

Bharat Biotech's track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 22,2020

Mumbai, Jun 22: After downgrading India's outlook to negative from stable, Fitch Ratings on Monday revised the outlook on nine Indian banks to negative.

The outlook on the Long-Term Issuer Default Ratings (IDR) was revised to negative from stable due to the banks' high dependence on the Centre to re-capitalise them.

Accordingly, the IDR outlook of the Export-Import Bank of India, the State Bank of India, the Bank of Baroda, the Bank of Baroda (New Zealand), the Bank of India, the Canara Bank, the Punjab National Bank, ICICI Bank and Axis Bank Ltd have been downgraded to negative.

"At the same time, Fitch has affirmed IDBI Bank Limited's (IDBI) IDR while maintaining the outlook at negative," Fitch said in a statement.

The rating actions follow Fitch's revision of the outlook on the 'BBB-' rating on India to negative from stable on June 18, due to the impact of the escalating coronavirus pandemic on India's economy.

"The IDRs for all the above Indian banks are support-driven and anchored to their respective SRFs," the statement said.

"They are based on Fitch's assessment of high to moderate probability of extraordinary state support for these banks, which takes into account our assessment of the sovereign's ability and propensity to provide extraordinary support."

According to the statement, the negative outlook on India's sovereign rating reflects an increasing strain on the state's ability to provide extraordinary support, due to the sovereign's limited fiscal space and the significant deterioration in fiscal metrics due to challenges from the COVID-19 pandemic.

"The rating action does not affect the banks' Viability Rating (VR). EXIM does not have a VR as its role as a policy bank makes an assessment of its standalone credit profile less meaningful."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 30,2020

New Delhi, Jul 30: Even as COVID-19 cases continue to surge in various parts of India, more than 1 million people have recovered and discharged till now, informed Rajesh Bhushan, Secretary, Ministry of Health, here on Thursday.

"More than 1 million people have recovered from COVID-19 in the country. This landmark recovery has been achieved because of the selfless work and dedication of our doctors, nurses and frontline workers," Bhushan said at a press conference.

Giving the number of cured persons, Bhushan said, "More than 1,020,000 patients have recovered. They have been discharged. It is a great achievement."

He said, "The recovery rate has shown positive trends. It was 7.85 per cent in April and today it is 64.4 per cent, which is another heartening news which tells us that whatever battle is put by the Union government in collaboration with state governments is showing results."

"Sixteen states of the country have a recovery rate that is more than the national average. Of these, Delhi has a recovery rate of 88 per cent, Ladakh 80 per cent, Haryana 78 per cent, Assam 76 per cent, Telangana 74 per cent, Tamil Nadu & Gujarat 73 per cent, Rajasthan 70 per cent, Madhya Pradesh 69 per cent and Goa 68 per cent," Bhushan said.

He said effective clinical management lead to a decrease in case fatality rate. In June it was 3.33 per cent and now 2.21 per cent.

Bhushan said the case fatality rate in India today is 2.21 per cent and it's among the lowest in the world. Twenty-four states and Union Territories have lesser fatality rate than that of the country.

Herd immunity in a country of the size and population of India can not be a strategic option. It can only be achieved through immunisation.

"Over 18,190,000 tests have been conducted in the country including RT-PCR and rapid antigen tests. There has been a week-on-week increase in average tests per day. India is conducting 324 test per 10 lakhs population per day," Bhushan said.

He added, three vaccine candidates, are in phase 3 clinical trial. These three are in the US, UK and China. In India, two indigenously developed vaccine candidates are in phase I and II of clinical trials. 

Trial of the first vaccine involves 1,150 subjects at eight sites, second on 1,000 subjects at five sites.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.